Pharmaron Shares Surge Over 5% on Lilly Manufacturing Pact for Orforglipron

Stock News03-12

Pharmaron (03759) opened sharply higher, rising more than 5% in early trading. At the time of writing, the stock was up 5.43% to HK$19.61, with a turnover of HK$6.4262 million. The move follows an announcement on March 11 that the company and Eli Lilly have entered into a manufacturing collaboration for Orforglipron, the first oral small molecule GLP-1 receptor agonist to be submitted for registration. Under the agreement, Lilly is expected to invest $200 million in Pharmaron to support its technical capabilities, with potential for further expansion based on future developments. This commercial manufacturing partnership for Orforglipron with Lilly marks a significant milestone for Pharmaron's formulation CDMO business.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment